Abstract
Using a MLL-AF9 knock-in mouse model, we discovered that consumption of a high-fat diet (HFD) accelerates the risk of developing acute myeloid leukemia (AML). This regimen increases the clusterization of FLT3 within lipid rafts on the cell surface of primitive hematopoietic cells, which overactivates this receptor as well as the downstream JAK/STAT signaling known to enhance the transformation of MLL-AF9 knock-in cells. Treatment of mice on a HFD with Quizartinib, a potent inhibitor of FLT3 phosphorylation, inhibits the JAK3/STAT3, signaling and finally antagonizes the accelerated development of AML that occurred following the HFD regimen. We can therefore conclude that, on a mouse model of AML, a HFD enforces the FLT3 signaling pathway on primitive hematopoietic cells and, in turn, improves the oncogenic transformation of MLL-AF9 knock-in cells and the leukemia initiation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Benzothiazoles / pharmacology
-
Cell Transformation, Neoplastic / genetics
-
Cell Transformation, Neoplastic / metabolism*
-
Diet, High-Fat*
-
Disease Models, Animal
-
Gene Expression Regulation, Leukemic
-
Hematopoietic Stem Cells / drug effects
-
Hematopoietic Stem Cells / metabolism*
-
Histone-Lysine N-Methyltransferase / genetics
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / metabolism*
-
Mice
-
Mice, Transgenic
-
Myeloid-Lymphoid Leukemia Protein / genetics
-
Nuclear Proteins / genetics
-
Phenylurea Compounds / pharmacology
-
Phosphorylation / drug effects
-
Signal Transduction / drug effects
-
Signal Transduction / physiology*
-
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
-
fms-Like Tyrosine Kinase 3 / metabolism*
Substances
-
Benzothiazoles
-
Mllt3 protein, mouse
-
Nuclear Proteins
-
Phenylurea Compounds
-
Myeloid-Lymphoid Leukemia Protein
-
quizartinib
-
Histone-Lysine N-Methyltransferase
-
Kmt2a protein, mouse
-
Flt3 protein, mouse
-
fms-Like Tyrosine Kinase 3